Brii’s Cocktail Active Against Coronavirus Subvariants, But Will It Succeed On The Market?
Executive Summary
The company announced data showing the two-antibody drug had strong activity against Omicron BA.4, BA.5 and BA.2.12.1, but on the US market it would compete against oral drugs.